Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Raal FJ, et al. Among authors: curcio d. N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32197277 Free article. Clinical Trial.
Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN.
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Golberg AC, Brunham LR, Curcio D, Wuerdeman E, Neild A, Kling D, Hsieh A, Dicklin MR, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Davidson MH. Nicholls SJ, et al. Among authors: curcio d. Am Heart J. 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024.05.002. Online ahead of print. Am Heart J. 2024. PMID: 38705341 Free article.
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH. Dunbar RL, et al. Among authors: curcio d. Lipids Health Dis. 2015 Sep 2;14:98. doi: 10.1186/s12944-015-0100-8. Lipids Health Dis. 2015. PMID: 26328624 Free PMC article. Clinical Trial.
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. Maki KC, et al. Among authors: curcio d. Clin Ther. 2013 Sep;35(9):1400-11.e1-3. doi: 10.1016/j.clinthera.2013.07.420. Epub 2013 Aug 30. Clin Ther. 2013. PMID: 23998969 Clinical Trial.
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, Davidson M. Offman E, et al. Among authors: curcio d. Vasc Health Risk Manag. 2013;9:563-73. doi: 10.2147/VHRM.S50464. Epub 2013 Oct 1. Vasc Health Risk Manag. 2013. PMID: 24124374 Free PMC article. Clinical Trial.
Autonomous micro-focus angle-resolved photoemission spectroscopy.
Ágústsson SÝ, Jones AJH, Curcio D, Ulstrup S, Miwa J, Mottin D, Karras P, Hofmann P. Ágústsson SÝ, et al. Among authors: curcio d. Rev Sci Instrum. 2024 May 1;95(5):055106. doi: 10.1063/5.0204663. Rev Sci Instrum. 2024. PMID: 38717271
117 results